INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH AND INNOVATIVE STUDIES
ISSN: 2820-7157
www.ijsrisjournal.com

December 2024 **Volume 3** **Number 6** **Pages 46-48**

Received Date: November 05, 2024 **Accepted Date:** November 26, 2024 **Published Date:** December 01, 2024

Available Online at https://www.ijsrisjournal.com/index.php/ojsfiles/article/view/259

https://doi.org/10.5281/zenodo.14260201

Childhood Acute Lymphoblastic Leukemia (ALL): Diagnosis, Treatment, and Management

Ahmed Hussain Almahdi[1], Sukinah Mohammed Albather[2], Mostafa Ali Alwahamed[3], Yaqoub Yousef Bushji[3], Shaima Saeed Alsalem[4], Abdullah Ahmed Alali[3], Hussain Ali Buhumud[5], Mousa Jawad Bu Muza[6], Abdullah Hasan Alzowayed[7], Abdullah Ayesh Alshalyan[7], Fadhel Radhi Alhawdar[8], Ahmad Salman Aljumaan[9], Mohammed Nabeel Al Hamed[10], Yaser Abdulmohsen Al Aghnam[7], Yahya Jassem Alnasser[7]

1. North Medical Tower
2. King Faisal Hospital
3. Mental Health Hospital
4. Mr.Ali Alsalman Center For Comprehensive Examination And Early Detection Of Tumours.
5. Prince Saud Bin Jalawy Hospital
6. Oyun City Hospital
7. King Fahad Hospital
8. Albandreya P H C
9. Primary Care Laboratory
10. Prince Abdulaziz Bin Mossad Hospital

ABSTRACT

Childhood Acute Lymphoblastic Leukemia (ALL) is the most common pediatric malignancy, accounting for approximately 25% of childhood cancers. With advancements in diagnostic tools, treatment protocols, and supportive care, survival rates for ALL have significantly improved, reaching nearly 90% in high-income countries. This review discusses the current approaches to diagnosing, treating, and managing childhood ALL, highlighting recent advancements in genomics, immunotherapy, and risk stratification strategies that continue to shape patient outcomes.

1. Introduction

Acute Lymphoblastic Leukemia (ALL) is a hematologic malignancy characterized by the uncontrolled proliferation of immature lymphoblasts in the bone marrow, blood, and other tissues. It is most prevalent in children aged 2-5 years, with a slight male predominance. Acute lymphoblastic leukemia (ALL) is a malignant transformation and proliferation of lymphoid progenitor cells in the bone marrow, blood and extramedullary sites. While 80% of ALL occurs in children, it represents a devastating disease when it occurs in adults. Within the United States, the incidence of ALL is estimated at 1.6 per 100 000 population(1). In 2016 alone, an estimated 6590 new cases were diagnosed, with over 1400 deaths due to ALL (American Cancer Society). The incidence of ALL follows a bimodal distribution, with the first peak occurring in childhood and a second peak occurring around the age of 50(2). While dose-intensification strategies have led to a significant improvement in outcomes for pediatric patients, prognosis for the elderly remains very poor. Despite a high rate of response to induction chemotherapy, only 30–40% of adult patients with ALL will achieve long-term remission(3). Early and accurate diagnosis, risk-adapted treatment, and effective supportive care are critical to improving survival and quality of life for affected children.

2. Diagnosis of ALL

2.1. Clinical Presentation

Children with ALL may present with symptoms resulting from bone marrow failure or leukemic infiltration, including:

- **Bone marrow failure:** Anemia, fatigue, pallor, thrombocytopenia (bruising, petechiae), and neutropenia (recurrent infections).
- **Leukemic infiltration:** Bone pain, hepatosplenomegaly, lymphadenopathy, and central nervous system (CNS) symptoms such as headache or cranial nerve palsies.

2.2. Laboratory and Diagnostic Tests

Diagnosis is confirmed through a combination of clinical and laboratory evaluations:

- **Complete Blood Count (CBC):** Typically reveals leukocytosis, anemia, and thrombocytopenia.
- **Bone Marrow Aspiration and Biopsy:** Presence of ≥20% lymphoblasts in the bone marrow confirms the diagnosis(4,5).
- **Immunophenotyping:** Flow cytometry distinguishes B-cell and T-cell ALL subtypes.
- **Cytogenetics and Molecular Testing:** Detection of chromosomal abnormalities, such as the Philadelphia chromosome (t(9;22)) or hyperdiploidy, aids in risk stratification.
- **Lumbar Puncture:** Evaluates CNS involvement.

3. Treatment of ALL

3.1. Risk Stratification

Treatment is guided by risk classification, which considers factors such as age, initial white blood cell (WBC) count, immunophenotype, cytogenetic abnormalities, and response to initial therapy.

3.2. Phases of Treatment

- **Induction Therapy:** Aims to achieve remission by eliminating >99% of leukemic cells. Common drugs include vincristine, corticosteroids (e.g., dexamethasone), L-asparaginase, and anthracyclines(5).
- **Consolidation (Intensification):** Prevents relapse by targeting residual disease. This phase involves high-dose methotrexate, cytarabine, and other chemotherapeutic agents(6).
- **Maintenance Therapy:** Administered over 2-3 years, primarily using oral methotrexate and mercaptopurine, to sustain remission.

3.3. CNS Prophylaxis

ALL commonly involves the CNS. Intrathecal chemotherapy (e.g., methotrexate) and cranial irradiation are used to prevent or treat CNS involvement(7).

3.4. Targeted Therapy

- **Tyrosine Kinase Inhibitors (TKIs):** Used for Philadelphia chromosome-positive ALL (e.g., imatinib, dasatinib).

- **Monoclonal Antibodies:** Blinatumomab (anti-CD19) and inotuzumab ozogamicin (anti-CD22) have shown efficacy in relapsed/refractory ALL.

3.5. Immunotherapy

Chimeric Antigen Receptor (CAR)-T cell therapy, targeting CD19-positive cells, has emerged as a promising option for relapsed/refractory ALL.

3.6. Hematopoietic Stem Cell Transplantation (HSCT)

Indicated for high-risk or relapsed patients, HSCT provides a curative option by replacing diseased marrow with healthy donor cells.

4. Management of Childhood ALL

4.1. Supportive Care

- **Infection Prevention:** Prophylactic antibiotics, antifungals, and vaccinations are crucial in immunosuppressed patients.
- **Nutritional Support:** Ensures adequate caloric and protein intake during intensive therapy phases.
- **Psychosocial Support:** Addresses the emotional and psychological needs of patients and families.

4.2. Monitoring and Follow-Up

- **Minimal Residual Disease (MRD) Monitoring:** Quantifies residual leukemic cells post-treatment to guide therapy adjustments.
- **Late Effects:** Long-term survivors require monitoring for late effects, including secondary malignancies, cardiotoxicity, and neurocognitive deficits.

5. Recent Advances in Childhood ALL

5.1. Genomic Insights

Advances in genomic profiling have identified novel subtypes of ALL (e.g., Ph-like ALL) with unique prognostic and therapeutic implications.

5.2. Precision Medicine

Tailored treatments based on genetic and molecular profiles improve efficacy while minimizing toxicity.

5.3. Emerging Therapies

- **Bispecific T-cell Engagers (BiTEs):** Redirect T-cells to target leukemic cells.
- **Checkpoint Inhibitors:** Under investigation for enhancing immune responses against leukemia(8).

6. Challenges and Future Directions

Despite remarkable progress, challenges remain in addressing relapsed/refractory cases, improving outcomes in low- and middle-income countries, and mitigating long-term treatment-related complications. Future research should focus on developing less toxic, more effective therapies and ensuring equitable access to care globally.

7. Conclusion

Childhood ALL represents a success story in pediatric oncology, with survival rates nearing 90% in developed countries. Advances in diagnosis, risk-adapted treatment, and supportive care have transformed ALL into a largely curable disease. However, continued efforts are needed to overcome disparities in outcomes and refine therapies to improve both survival and quality of life for all children with ALL.

References

1.Krapcho M et al. HNNA. SEER Cancer Statistics Review 1975-2013 National Cancer Institute SEER Cancer Statistics Review 1975-2013 National Cancer Institute. SEER Cancer Statistics Review, 1975-2013,

2.National Cancer Institute Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016. 2016;

3.Künz T, Hauswirth AW, Hetzenauer G, Rudzki J, Nachbaur D, Steiner N. Changing Landscape in the Treatment of Adult Acute Lymphoblastic Leukemia (ALL). Vol. 14, Cancers. 2022.

4.Jabbour E, O'Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Vol. 121, Cancer. 2015.

5.Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Vol. 6, Mediterranean Journal of Hematology and Infectious Diseases. 2014.

6.Duffield AS, Mullighan CG, Borowitz MJ. International Consensus Classification of acute lymphoblastic leukemia/lymphoma. Vol. 482, Virchows Archiv. 2023.

7.Toksvang LN, Lee SHR, Yang JJ, Schmiegelow K. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Vol. 36, Leukemia. 2022.

8.Kopmar NE, Cassaday RD. How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia. Vol. 141, Blood. 2023.

9.Pui CH, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50(3).